Bionomics to Participate in Upcoming September 2022 Investor Conferences

ADELAIDE, Australia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will participate in the following upcoming investor conferences in September:

  • Citi’s 17th Annual BioPharma Conference
    • Taking place in-person in Boston on September 8th
  • H.C. Wainwright 24th Annual Global Investment Conference
    • Company Presentation: September 12th at 12:30pm ET in New York City
  • Ladenburg Thalmann Healthcare Conference 2022
    • Company Presentation: September 29th at 4:00pm ET in New York City

An audio webcast link for select events, when available, will be posted to Bionomics’ website in the Events and Presentations page of the Investors section.

Released on authority of the Executive Chairman.

FOR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Mr. Connor Bernstein
Vice President, Strategy and Corporate Development
+1 (650) 524-5143
cbernstein@bionomics.com.au
Investor Relations
Kevin Gardner
kgardner@lifesciadvisors.com

About Bionomics Limited
Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
www.bionomics.com.au


Primary Logo

Back to news